Projected estimates of cancer in Canada in 2022
![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
Background: Regular cancer surveillance is crucial for understanding where progress is being made and where more must be done. We sought to provide an overview of the expected burden of cancer in Canada in 2022.
Methods: We obtained data on new cancer incidence from the National Cancer Incidence Reporting System (1984–1991) and Canadian Cancer Registry (1992–2018). Mortality data (1984–2019) were obtained from the Canadian Vital Statistics — Death Database. We projected cancer incidence and mortality counts and rates to 2022 for 22 cancer types by sex and province or territory. Rates were age standardized to the 2011 Canadian standard population.
Results: An estimated 233 900 new cancer cases and 85 100 cancer deaths are expected in Canada in 2022. We expect the most commonly diagnosed cancers to be lung overall (30 000), breast in females (28 600) and prostate in males (24 600). We also expect lung cancer to be the leading cause of cancer death, accounting for 24.3% of all cancer deaths, followed by colorectal (11.0%), pancreatic (6.7%) and breast cancers (6.5%). Incidence and mortality rates are generally expected to be higher in the eastern provinces of Canada than the western provinces.
Interpretation: Although overall cancer rates are declining, the number of cases and deaths continues to climb, owing to population growth and the aging population. The projected high burden of lung cancer indicates a need for increased tobacco control and improvements in early detection and treatment. Success in breast and colorectal cancer screening and treatment likely account for the continued decline in their burden. The limited progress in early detection and new treatments for pancreatic cancer explains why it is expected to be the third leading cause of cancer death in Canada.
- Accepted March 3, 2022.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
In this issue
Article extras
Article tools
Jump to section
Related Articles
Cited By...
- Traitement cible oral contre le cancer du poumon non a petites cellules
- Percees dans la prise en charge de lhypernephrome
- Evidence-based truths about the benefit of cancer screening
- Oral targeted therapy for the treatment of non-small cell lung carcinoma
- Comparing immediate postoperative outcomes of different VATS approaches for anatomical lung resection: a single-centre retrospective study
- Advances in the management of renal cell carcinoma
- A Lipidomics Approach to Determine the Role of Lipids and its Crosstalk with Autophagy in Lung Cancer Metastasis
- Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer
- Depistage du cancer de la prostate chez les hommes noirs au Canada : Argument en faveur des soins stratifies en fonction du risque
- Prostate cancer screening in Black men in Canada: a case for risk-stratified care
- Transition de la cytologie a la detection du VPH pour le depistage du cancer du col de luterus au Canada
- Real-time molecular classification of leukemias
- Shifting from cytology to HPV testing for cervical cancer screening in Canada